Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of COVID-19-related data drift on machine-learning prognostic models predicting 30-day opioid-related emergency department visits, hospitalisation or mortality: a population-level administrative data study in Alberta, Canada.

BMJ open·2026
Same author

Correction: Influence of the COVID-19 pandemic on chronic disease management among indigenous people in Canada.

Frontiers in public health·2026
Same author

'It's not just diabetes': implementation enablers and barriers of an indigenous-focused virtual diabetes care clinic using the Consolidated Framework for Implementation Research (CFIR) - a qualitative assessment.

BMJ open·2026
Same author

Becoming Invisible: How Mental Health Systems Erode Selfhood in Young Adults With Mental Health-Related Disabilities.

Qualitative health research·2026
Same author

Mental Health-Related Disabilities, Healthcare Utilization, and Access in Young Adults with Anxiety and Depression: A Scoping Review.

Administration and policy in mental health·2026
Same author

Influence of the COVID-19 pandemic on chronic disease management among indigenous people in Canada.

Frontiers in public health·2026

Related Experiment Video

Updated: Jun 3, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Wrongfully accused: metformin use in heart failure.

Dean T Eurich1, Finlay A McAlister

  • 1School of Public Health, University of Alberta, Edmonton, AL, T6G 2T4, Canada. deurich@ualberta.ca

Expert Review of Cardiovascular Therapy
|April 2, 2011
PubMed
Summary
This summary is machine-generated.

Metformin, a common diabetes drug, may improve outcomes for patients with heart failure. A study found improved results for those with diabetes and heart failure using metformin.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Related Experiment Videos

Last Updated: Jun 3, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Metformin is a widely used first-line oral anti-hyperglycemic agent for Type 2 diabetes.
  • Metformin is recommended by major clinical practice guidelines for its efficacy, tolerability, and weight management benefits.
  • Randomized controlled trials have demonstrated metformin's ability to reduce mortality in newly diagnosed Type 2 diabetes patients.

Discussion:

  • The use of metformin in patients with heart failure has been a subject of controversy.
  • This review focuses on an observational study by Aguilar et al. published in Circulation - Heart Failure.
  • The study investigated metformin use in ambulatory patients with diabetes and heart failure.

Key Insights:

  • The observational study by Aguilar et al. reported improved outcomes in patients with diabetes and heart failure who were using metformin.
  • This suggests a potential benefit of metformin in this specific patient population.
  • Further research may be warranted to confirm these findings and elucidate the mechanisms involved.

Outlook:

  • The findings suggest a potential re-evaluation of metformin use in diabetic patients with heart failure.
  • Further investigation into the safety and efficacy of metformin in heart failure patients is needed.
  • This could lead to revised clinical practice guidelines regarding metformin prescription in this demographic.